These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 1735010)
1. Phase I-II trial of high-dose melphalan in previously untreated stage III multiple myeloma: Cancer and Leukemia Group B study 8512. Case DC; Coleman M; Gottlieb A; McCarroll K Cancer Invest; 1992; 10(1):11-7. PubMed ID: 1735010 [TBL] [Abstract][Full Text] [Related]
2. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma. Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248 [TBL] [Abstract][Full Text] [Related]
8. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039 [TBL] [Abstract][Full Text] [Related]
9. High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial. Vesole DH; Crowley JJ; Catchatourian R; Stiff PJ; Johnson DB; Cromer J; Salmon SE; Barlogie B J Clin Oncol; 1999 Jul; 17(7):2173-9. PubMed ID: 10561273 [TBL] [Abstract][Full Text] [Related]
10. [First-line treatment of severe myelomas of the young subject by high-dose melphalan]. Harousseau JL; Milpied N; Guilhot F; Garand R; Bourhis JH Presse Med; 1988 Aug 27-Sep 3; 17(29):1471-4. PubMed ID: 2971190 [TBL] [Abstract][Full Text] [Related]
11. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). Pönisch W; Mitrou PS; Merkle K; Herold M; Assmann M; Wilhelm G; Dachselt K; Richter P; Schirmer V; Schulze A; Subert R; Harksel B; Grobe N; Stelzer E; Schulze M; Bittrich A; Freund M; Pasold R; Friedrich T; Helbig W; Niederwieser D; J Cancer Res Clin Oncol; 2006 Apr; 132(4):205-12. PubMed ID: 16402269 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428 [TBL] [Abstract][Full Text] [Related]
13. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. Comenzo RL; Hassoun H; Kewalramani T; Klimek V; Dhodapkar M; Reich L; Teruya-Feldstein J; Fleisher M; Filippa D; Nimer SD Leukemia; 2006 Feb; 20(2):345-9. PubMed ID: 16319952 [TBL] [Abstract][Full Text] [Related]
14. Short course intermediate dose intravenous melphalan therapy in myeloma--relation to early emergence of drug resistance (phase II study). Sviland L; Leggat H; Harris AL; Bird G; Proctor SJ Acta Haematol; 1987; 78(4):233-8. PubMed ID: 3122488 [TBL] [Abstract][Full Text] [Related]
16. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. Cunningham D; Paz-Ares L; Milan S; Powles R; Nicolson M; Hickish T; Selby P; Treleavan J; Viner C; Malpas J J Clin Oncol; 1994 Apr; 12(4):759-63. PubMed ID: 8151319 [TBL] [Abstract][Full Text] [Related]
17. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521 [TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments. Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682 [TBL] [Abstract][Full Text] [Related]